About me
Matthew Miessau is a Principal with Epidarex Capital, a Bethesda, Maryland based venture capital firm that finds, invests in, and builds early-stage breakthrough life sciences companies in emerging hubs in the US and UK. Matthew is actively involved in deal sourcing, including expanding Epidarex Capital’s reach and relationships with key universities in the US. He is focused on conducting due diligence on prospective investments on both sides of the Atlantic, assisting in portfolio management, and supporting the firm’s fundraising efforts. Matthew serves as a Director for Clyde Biosciences and is a Board Observer for Nyra Medical, RapidPulse, AdoRx Therapeutics and Epidarex Exeed. Matthew is currently an instructor at the NIH Foundation for Advanced Education in the Sciences (FAES), teaching Biomedical Business Development for Scientists. In his role as an instructor, he leverages his experience at Epidarex to provide real world insights to NIH researchers interested in learning about the commercialization of life science innovations. Matthew holds an M.S. in Biotechnology and a B.S. in Biochemistry from Georgetown University.
